Signifier Medical Technologies Ltd has hit the 50,000 therapy session milestone with its eXciteOSA sleep apnea therapy device.
EXciteOSA is a daytime treatment for snoring and mild obstructive sleep apnea (OSA) and received FDA authorization and clearance for marketing in February 2021. The device is used for 20 minutes per day for six weeks and then twice per week thereafter for maintenance.
“We are thrilled with what this milestone represents for the improvement of patient care,” says Akhil Tripathi, CEO, and co-founder of Signifier Medical Technologies, in a release. “Being a comfortable and effective treatment has helped patients stay adherent to their therapy and feel the difference. 50,000 sessions is only the beginning, and we look forward to supporting the millions of people who suffer from mild OSA and snoring.”
Unlike devices used while patients are asleep, eXciteOSA is the first marketed device designed to be used while awake. It works by applying neuromuscular electrical stimulation on the genioglossus muscle—the major muscle that forms the tongue mass. Neuromuscular electrical stimulation creates contractions of the tongue muscle, enhancing function and endurance so that after 6 weeks of therapy, the tongue stays in an ideal position for optimal airflow.
“EXciteOSA has been a life-saver for me and my family. The device has significantly reduced my snoring after just 2 weeks of use,” says Jessie Cadet-Legros, an eXciteOSA patient, in a release. “It was easy to find 20 minutes during the day to use it and the results have paid off. My husband now sleeps better without my snoring, and so do I.”